Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. 1977

M Gellert, and K Mizuuchi, and M H O'Dea, and T Itoh, and J I Tomizawa

ATP-dependent DNA supercoiling catalyzed by Escherichia coli DNA gyrase was inhibited by oxolinic acid, a compound similar to but more potent than nalidixic acid and a known inhibitor of DNA replication in E. coli. The supercoiling activity of DNA gyrase purified from nalidixic acid-resistant mutant (nalA(R)) bacteria was resistant to oxolinic acid. Thus, the nalA locus is responsible for a second component needed for DNA gyrase activity in addition to the component determined by the previously described locus for resistance to novobiocin and coumermycin (cou). Supercoiling of lambda DNA in E. coli cells was likewise inhibited by oxolinic acid, but was resistant in the nalA(R) mutant. The inhibition by oxolinic acid of colicin E1 plasmid DNA synthesis in a cell-free system was largely relieved by adding resistant DNA gyrase. In the absence of ATP, DNA gyrase preparations relaxed supercoiled DNA; this activity was also inhibited by oxolinic acid, but not by novobiocin. It appears that the oxolinic acid-sensitive component of DNA gyrase is involved in the nicking-closing activity required in the supercoiling reaction. In the presence of oxolinic acid, DNA gyrase forms a complex with DNA, which can be activated by later treatment with sodium dodecyl sulfate and a protease to produce double-strand breaks in the DNA. This process has some similarities to the known properties of relaxation complexes.

UI MeSH Term Description Entries
D009268 Nalidixic Acid A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA GYRASE. Nalidixin,Nalidixate Sodium,Nalidixate Sodium Anhydrous,Nevigramon,Sodium Nalidixic Acid, Anhydrous,Sodium Nalidixic Acid, Monohydrate,Acid, Nalidixic,Anhydrous, Nalidixate Sodium,Sodium Anhydrous, Nalidixate,Sodium, Nalidixate
D010093 Oxolinic Acid Synthetic antimicrobial related to NALIDIXIC ACID and used in URINARY TRACT INFECTIONS. Gramurin,Sodium Oxolinate,Acid, Oxolinic,Oxolinate, Sodium
D004269 DNA, Bacterial Deoxyribonucleic acid that makes up the genetic material of bacteria. Bacterial DNA
D004278 DNA, Superhelical Circular duplex DNA isolated from viruses, bacteria and mitochondria in supercoiled or supertwisted form. This superhelical DNA is endowed with free energy. During transcription, the magnitude of RNA initiation is proportional to the DNA superhelicity. DNA, Supercoiled,DNA, Supertwisted,Supercoiled DNA,Superhelical DNA,Supertwisted DNA
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli

Related Publications

M Gellert, and K Mizuuchi, and M H O'Dea, and T Itoh, and J I Tomizawa
November 1981, Journal of bacteriology,
M Gellert, and K Mizuuchi, and M H O'Dea, and T Itoh, and J I Tomizawa
May 1988, Biochemical pharmacology,
M Gellert, and K Mizuuchi, and M H O'Dea, and T Itoh, and J I Tomizawa
September 1980, Mutation research,
M Gellert, and K Mizuuchi, and M H O'Dea, and T Itoh, and J I Tomizawa
April 2009, Indian journal of biochemistry & biophysics,
M Gellert, and K Mizuuchi, and M H O'Dea, and T Itoh, and J I Tomizawa
October 2017, ACS chemical biology,
M Gellert, and K Mizuuchi, and M H O'Dea, and T Itoh, and J I Tomizawa
November 1985, Antimicrobial agents and chemotherapy,
M Gellert, and K Mizuuchi, and M H O'Dea, and T Itoh, and J I Tomizawa
July 1986, The Journal of biological chemistry,
M Gellert, and K Mizuuchi, and M H O'Dea, and T Itoh, and J I Tomizawa
January 1998, Bioorganic & medicinal chemistry letters,
M Gellert, and K Mizuuchi, and M H O'Dea, and T Itoh, and J I Tomizawa
January 1985, Proceedings of the National Academy of Sciences of the United States of America,
M Gellert, and K Mizuuchi, and M H O'Dea, and T Itoh, and J I Tomizawa
July 2017, Bioscience, biotechnology, and biochemistry,
Copied contents to your clipboard!